. 2019 Aug 27;25:6436–6445. doi: 10.12659/MSM.916955

Table 3.

Percentage changes from baseline of pain score in the included trials.

Study	Outcomes	Treatments	No. of patients	Baseline	% Change from baseline at different time points
Study	Outcomes	Treatments	No. of patients	Baseline	Day 7–14	Day 28–30	Final visit
Atchia 2011	NRS pain (0–10)	Durolane	19	6.2	NS	NS	NS
Atchia 2011	NRS pain (0–10)	Saline	19	6.3	NS	NS	NS
Brander 2018	WOMAC Pain score	Hylan G-F 20	182	6.42±0.06	NA	−27.6%^***	−34.4%^***
Brander 2018	WOMAC Pain score	Saline	175	6.48±0.07	NA	−30.1%^***	−37.3%^***
Migliore 2009	Pain score (0–10 VAS)	Hyalubrix	22	6.4±1.94	NA	NA	−29.7%^**,^#
Migliore 2009	Pain score (0–10 VAS)	Mepivacaine	20	6.0±1.94	NA	NA	−16.7%^**
Qvistgaard 2006	Pain on walking (0–100 mm VAS)	Hyalgan	33	49.2±24.8	−20.3%^*	−22.4%^*	−22.4%^*
Qvistgaard 2006	Pain on walking (0–100 mm VAS)	Saline	36	42.4±19.7	+4.7%	−2.4%	−11.8%
Richette 2009	Pain score (0–100 mm VAS)	Adant	42	58.4±14.2	NA	NA	−13.4%
Richette 2009	Pain score (0–100 mm VAS)	Saline	43	60.4±10.2	NA	NA	−15.1%

NRS – numerical rating scale (0–10); NS – not significant; WOMAC – Western Ontario and McMaster Universities Arthritis Index; NA – not available; VAS – visual analogue scale.

Achieved statistical significance (^* p<0.05; ^** p<0.01; ^*** p<0.001) compared to baseline;

achieved statistical significance (^# p<0.05; ^## p<0.01; ^### p<0.001) compared to placebo control.